Window (physical object)
Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026
Aktis Oncology IPO; AKTS; 2026 biotech IPOs; IPO bounce; radiopharmaceuticals; Eli Lilly backing; biotech capital markets; Nectin-4; B7-H3; IPO window 2026
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead
Endpoints 100; E100 survey; biotech CEOs; biopharma executives; industry sentiment; market recovery; dealmaking; IPO window; Trump administration; FDA reorganization; tariffs; 2025 outlook